Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Deferred Taxes (2016 - 2025)

Historic Deferred Taxes for Dexcom (DXCM) over the last 17 years, with Q4 2025 value amounting to $78.9 million.

  • Dexcom's Deferred Taxes rose 22469.14% to $78.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $182.2 million, marking a year-over-year increase of 51598.17%. This contributed to the annual value of $182.2 million for FY2025, which is 51598.17% up from last year.
  • Dexcom's Deferred Taxes amounted to $78.9 million in Q4 2025, which was up 22469.14% from $118.0 million recorded in Q3 2025.
  • Dexcom's Deferred Taxes' 5-year high stood at $118.0 million during Q3 2025, with a 5-year trough of -$85.0 million in Q3 2023.
  • For the 5-year period, Dexcom's Deferred Taxes averaged around $3.9 million, with its median value being -$2.4 million (2021).
  • In the last 5 years, Dexcom's Deferred Taxes plummeted by 128947.37% in 2022 and then surged by 111724.14% in 2025.
  • Dexcom's Deferred Taxes (Quarter) stood at $9.1 million in 2021, then soared by 251.65% to $32.0 million in 2022, then surged by 154.69% to $81.5 million in 2023, then crashed by 70.18% to $24.3 million in 2024, then soared by 224.69% to $78.9 million in 2025.
  • Its Deferred Taxes was $78.9 million in Q4 2025, compared to $118.0 million in Q3 2025 and -$8.9 million in Q2 2025.